WHO SMART Guidelines - HIV
0.3.0 - ci-build
WHO SMART Guidelines - HIV - Local Development build (v0.3.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Active as of 2024-10-30 |
{
"resourceType" : "ValueSet",
"id" : "HIV.D.DE466",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareablevalueset"🔗 ,
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishablevalueset"🔗 ,
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-computablevalueset"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet HIV.D.DE466</b></p><a name=\"HIV.D.DE466\"> </a><a name=\"hcHIV.D.DE466\"> </a><a name=\"HIV.D.DE466-en-US\"> </a><ul><li>Include these codes as defined in <a href=\"CodeSystem-HIVConcepts.html\"><code>http://smart.who.int/hiv/CodeSystem/HIVConcepts</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE467\">HIV.D.DE467</a></td><td>Gastrointestinal</td><td>Treatment-limiting toxicity due to GI issues (nausea, diarrhoea, abdominal pain, vomiting)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE468\">HIV.D.DE468</a></td><td>Skin issues</td><td>Treatment-limiting toxicity due to skin issues (rash, hypersensitivity reaction)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE469\">HIV.D.DE469</a></td><td>Peripheral neuropathy</td><td>Treatment-limiting toxicity due to peripheral neuropathy (burning/numbness/ tingling)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE470\">HIV.D.DE470</a></td><td>Central nervous system symptoms</td><td>Treatment-limiting toxicity due to central nervous system symptoms (dizzy, anxiety, nightmare, depression, seizures)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE471\">HIV.D.DE471</a></td><td>Weight gain</td><td>Treatment-limiting toxicity due to weight gain</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE472\">HIV.D.DE472</a></td><td>Hepatic dysfunction</td><td>Treatment-limiting toxicity due to hepatic dysfunction (jaundice)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE473\">HIV.D.DE473</a></td><td>Haematological disorders</td><td>Treatment-limiting toxicity due to haematological (anaemia, neutropenia) disorders</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE474\">HIV.D.DE474</a></td><td>Fatigue</td><td>Treatment-limiting toxicity due to fatigue</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE475\">HIV.D.DE475</a></td><td>Headache</td><td>Treatment-limiting toxicity due to headache</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE476\">HIV.D.DE476</a></td><td>Bone dysfunction</td><td>Treatment-limiting toxicity due to bone dysfunction (fractures, osteopenia)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE477\">HIV.D.DE477</a></td><td>Metabolic symptoms</td><td>Treatment-limiting toxicity due to metabolic symptoms (body fat changes, hyperglycaemia, dyslipidaemia)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE478\">HIV.D.DE478</a></td><td>Kidney dysfunction</td><td>Treatment-limiting toxicity due to kidney dysfunction (nephrolithiasis, renal insufficiency)</td></tr><tr><td><a href=\"CodeSystem-HIVConcepts.html#HIVConcepts-HIV.46D.46DE479\">HIV.D.DE479</a></td><td>Unexpected adverse drug reaction</td><td>Client experienced an unexpected adverse drug reaction</td></tr></table></li></ul></div>"
},
"url" : "http://smart.who.int/hiv/ValueSet/HIV.D.DE466",
"version" : "0.3.0",
"name" : "HIVDDE466",
"title" : "Type of treatment-limiting toxicity ValueSet",
"status" : "active",
"experimental" : true,
"date" : "2024-10-30T19:04:31+00:00",
"publisher" : "WHO",
"contact" : [
{
"name" : "WHO",
"telecom" : [
{
"system" : "url",
"value" : "http://who.int"
}
]
}
],
"description" : "Value set of type of treatment-limiting toxicity experienced by client. Treatment-limiting toxicity is defined as a serious adverse drug reaction that results in drug discontinuation or substitution. In addition, any reaction that leads to treatment interruption or requires changing the drug or regimen because of an adverse drug reaction is also considered a serious adverse drug reaction.",
"compose" : {
"include" : [
{
"system" : "http://smart.who.int/hiv/CodeSystem/HIVConcepts",
"concept" : [
{
"code" : "HIV.D.DE467",
"display" : "Gastrointestinal"
},
{
"code" : "HIV.D.DE468",
"display" : "Skin issues"
},
{
"code" : "HIV.D.DE469",
"display" : "Peripheral neuropathy"
},
{
"code" : "HIV.D.DE470",
"display" : "Central nervous system symptoms"
},
{
"code" : "HIV.D.DE471",
"display" : "Weight gain"
},
{
"code" : "HIV.D.DE472",
"display" : "Hepatic dysfunction"
},
{
"code" : "HIV.D.DE473",
"display" : "Haematological disorders"
},
{
"code" : "HIV.D.DE474",
"display" : "Fatigue"
},
{
"code" : "HIV.D.DE475",
"display" : "Headache"
},
{
"code" : "HIV.D.DE476",
"display" : "Bone dysfunction"
},
{
"code" : "HIV.D.DE477",
"display" : "Metabolic symptoms"
},
{
"code" : "HIV.D.DE478",
"display" : "Kidney dysfunction"
},
{
"code" : "HIV.D.DE479",
"display" : "Unexpected adverse drug reaction"
}
]
}
]
}
}